Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Ontology highlight
ABSTRACT: Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually diagnosed in advanced stages due to late symptom manifestation with very limited therapeutic options, which leads to ineffective intervention and dismal prognosis. For a decade, tyrosine kinase inhibitors (TKIs) have offered an overall survival (OS) benefit when used in a first-line (sorafenib and lenvatinib) and second-line setting (regorafenib and cabozantinib) in advanced HCC, while long-term response remains unsatisfactory due to the onset of primary or acquired resistance. Recently, immunotherapy has emerged as a promising therapy in the treatment of several solid tumors, such as melanoma and non-small cell lung cancer. Moreover, as the occurrence of HCC is associated with immune tolerance and
SUBMITTER: Xing R
PROVIDER: S-EPMC8660685 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature
ACCESS DATA